The stock of Myokardia Inc (NASDAQ:MYOK) is a huge mover today! The stock increased 2.13% or $0.34 during the last trading session, hitting $16.34. About 150,340 shares traded hands. Myokardia Inc (NASDAQ:MYOK) has risen 126.31% since February 26, 2016 and is uptrending. It has outperformed by 115.88% the S&P500.
The move comes after 7 months positive chart setup for the $502.84 million company. It was reported on Oct, 1 by Barchart.com. We have $19.61 PT which if reached, will make NASDAQ:MYOK worth $100.57 million more.
Analysts await Myokardia Inc (MYOK) to report earnings on November, 16. They expect $-0.35 earnings per share, up 87.41% or $2.43 from last year’s $-2.78 per share. After $-0.37 actual earnings per share reported by Myokardia Inc for the previous quarter, Wall Street now forecasts -5.41% EPS growth.
Myokardia Inc (NASDAQ:MYOK) Ratings Coverage
Out of 5 analysts covering MyoKardia (NASDAQ:MYOK), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. MyoKardia has been the topic of 5 analyst reports since November 23, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Monday, November 23 by Credit Suisse. The firm has “Outperform” rating by Wedbush given on Monday, November 23. Cowen & Co initiated the stock with “Outperform” rating in Monday, November 23 report. The stock of Myokardia Inc (NASDAQ:MYOK) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The company was initiated on Wednesday, July 20 by BMO Capital Markets.
According to Zacks Investment Research, “MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy, DCM-1, treats heritable dilated cardiomyopathy by restoring normal contractility in the diseased DCM heart, HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients and LUS-1, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart, which are in different clinical trial. MyoKardia, Inc. is headquartered in San Francisco, California.”
More news for Myokardia Inc (NASDAQ:MYOK) were recently published by: Quotes.Wsj.com, which released: “MyoKardia Inc. MYOK (US: Nasdaq)” on October 24, 2015. Marketwatch.com‘s article titled: “MyoKardia initiated at outperform at Credit Suisse” and published on October 29, 2015 is yet another important article.
MYOK Company Profile
MyoKardia, Inc., incorporated on June 8, 2012, is a clinical-stage biopharmaceutical company. The Firm focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Firm is engaged in the business of developing and commercializing therapeutics. The Firm has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of approximately two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). The Company’s lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM. In preclinical models of HCM, MYK-461 has been shown to prevent and reverse disease progression and to reduce left ventricular outflow tract obstruction. The Firm is evaluating MYK-461 in over three Phase I clinical trials, including approximately two single ascending dose (SAD) trials and over one multiple ascending dose (MAD) trial. In its first Phase I clinical trial, the Company has demonstrated proof of mechanism, or the ability of MYK-461 to reduce cardiac muscle contraction.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.